CY2210B1 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- CY2210B1 CY2210B1 CY0000066A CY0000066A CY2210B1 CY 2210 B1 CY2210 B1 CY 2210B1 CY 0000066 A CY0000066 A CY 0000066A CY 0000066 A CY0000066 A CY 0000066A CY 2210 B1 CY2210 B1 CY 2210B1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical composition
- macrolide
- provides
- dimethyisosorbide
- cyclosporine
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000004530 micro-emulsion Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Colloid Chemistry (AREA)
- Cosmetics (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9421613A GB9421613D0 (en) | 1994-10-26 | 1994-10-26 | Organic compounds |
| GB9422084A GB9422084D0 (en) | 1994-11-02 | 1994-11-02 | Organic compounds |
| GBGB9425353.1A GB9425353D0 (en) | 1994-12-15 | 1994-12-15 | Organic compounds |
| GBGB9517133.6A GB9517133D0 (en) | 1995-08-22 | 1995-08-22 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY2210B1 true CY2210B1 (en) | 2002-11-08 |
Family
ID=27451224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY0000066A CY2210B1 (en) | 1994-10-26 | 2000-12-01 | Pharmaceutical composition |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP0787011B1 (enExample) |
| JP (3) | JPH10509699A (enExample) |
| KR (2) | KR100541198B1 (enExample) |
| CN (3) | CN1679938A (enExample) |
| AT (1) | ATE411800T1 (enExample) |
| AU (1) | AU714360B2 (enExample) |
| BR (1) | BR9509496A (enExample) |
| CA (1) | CA2200967C (enExample) |
| CY (1) | CY2210B1 (enExample) |
| CZ (1) | CZ289838B6 (enExample) |
| DE (2) | DE19581805T1 (enExample) |
| ES (1) | ES2316150T3 (enExample) |
| FI (1) | FI119497B (enExample) |
| HU (1) | HU225535B1 (enExample) |
| IL (3) | IL115742A (enExample) |
| MY (1) | MY129435A (enExample) |
| NO (2) | NO323078B1 (enExample) |
| NZ (1) | NZ295655A (enExample) |
| PE (1) | PE52896A1 (enExample) |
| PL (1) | PL184368B1 (enExample) |
| PT (1) | PT787011E (enExample) |
| SK (2) | SK285809B6 (enExample) |
| TR (2) | TR199500299A2 (enExample) |
| TW (1) | TW308544B (enExample) |
| WO (1) | WO1996013273A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| NZ280689A (en) * | 1995-12-15 | 1997-08-22 | Bernard Charles Sherma Sherman | Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol |
| US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
| JP4221762B2 (ja) * | 1997-04-11 | 2009-02-12 | アステラス製薬株式会社 | 医薬組成物 |
| US6008191A (en) * | 1997-09-08 | 1999-12-28 | Panacea Biotec Limited | Pharmaceutical compositions containing cyclosporin |
| US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
| IN188719B (enExample) * | 1997-09-08 | 2002-11-02 | Panacea Biotec Ltd | |
| US6346511B1 (en) | 1997-09-08 | 2002-02-12 | Panacea Biotec Limited | Pharmaceutical composition comprising cyclosporin |
| US6284268B1 (en) | 1997-12-10 | 2001-09-04 | Cyclosporine Therapeutics Limited | Pharmaceutical compositions containing an omega-3 fatty acid oil |
| GB2380673B (en) * | 1998-03-06 | 2003-05-28 | Novartis Ag | Emulsion preconcentrates containing cyclosporin or a macrolide |
| RU2235554C2 (ru) * | 1998-03-06 | 2004-09-10 | Новартис Аг | Предварительно приготовленные эмульсионные концентраты, содержащие циклоспорин или макролид |
| ID25908A (id) * | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| AU3843999A (en) * | 1998-05-07 | 1999-11-23 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
| TWI241915B (en) * | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
| TW537894B (en) * | 1998-05-26 | 2003-06-21 | Novartis Ag | A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist |
| GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| SE9804192D0 (sv) * | 1998-12-03 | 1998-12-03 | Scotia Lipidteknik Ab | New formulation |
| IL143604A0 (en) | 1998-12-30 | 2002-04-21 | Dexcel Ltd | Dispersable concentrate for the delivery of cyclosporin |
| ES2232195T3 (es) * | 1999-01-28 | 2005-05-16 | Dinesh Shantilal Patel | Solucion parenteral de propofol (2,6-diisopropilfenol) y 2,5-di-o-metil-1,4;3,6-dianhidro-d-glucitol como solvente. |
| GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| WO2000067773A2 (en) | 1999-05-10 | 2000-11-16 | Novartis Ag | Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
| GB9912476D0 (en) | 1999-05-28 | 1999-07-28 | Novartis Ag | Organic compounds |
| DE19925001A1 (de) * | 1999-05-31 | 2000-12-07 | Pharma Concepts Gmbh & Co Kg | Flüssiges Konzentrat |
| WO2000076478A1 (en) | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| US8895064B2 (en) | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| KR100342942B1 (ko) * | 1999-07-05 | 2002-07-02 | 민경윤 | 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물 |
| US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| US7919113B2 (en) | 1999-12-30 | 2011-04-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dispersible concentrate lipospheres for delivery of active agents |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| DE10024451A1 (de) * | 2000-05-18 | 2001-11-29 | Asta Medica Ag | Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung |
| IT1318539B1 (it) * | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| ES2292496T3 (es) * | 2000-09-18 | 2008-03-16 | Rpg Life Sciences Limited | Formulacion autoemulsionable con elevada actividad inmunosupresora y bioabsorbente. |
| JP2002193790A (ja) * | 2000-12-27 | 2002-07-10 | Lion Corp | 水難溶性薬剤含有水中油型エマルジョン及びその製造方法 |
| CN1551767A (zh) | 2001-02-19 | 2004-12-01 | ��˹��ŵ�� | 癌症的治疗 |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| EP1435910B9 (en) | 2001-10-19 | 2010-02-03 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
| CN100346785C (zh) * | 2001-10-25 | 2007-11-07 | 迪内希尚蒂拉尔·帕特尔 | 选择性环氧化酶ⅱ抑制剂的新型制剂 |
| RU2344821C2 (ru) | 2002-07-30 | 2009-01-27 | Уайт | Парентеральные композиции, содержащие гидроксиэфиры рапамицина |
| US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
| IL159729A0 (en) * | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
| CN101185638B (zh) * | 2004-10-09 | 2011-04-06 | 山西中医学院 | 一种微乳制剂及其制备方法 |
| CN100381175C (zh) * | 2004-10-09 | 2008-04-16 | 山西中医学院 | 一种微乳制剂及其制备方法 |
| GB0504950D0 (en) * | 2005-03-10 | 2005-04-20 | Novartis Ag | Organic compositions |
| CN1872058B (zh) * | 2005-05-31 | 2011-03-30 | 华北制药集团新药研究开发有限责任公司 | 一种含大环内酯类化合物的药物组合物 |
| PT2275103E (pt) | 2005-11-21 | 2014-07-24 | Novartis Ag | Inibidores de mtor para o tratamento de tumores endócrinos |
| US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
| CN1919194A (zh) * | 2006-08-17 | 2007-02-28 | 刘瑜玲 | 西罗莫司的液体组合物 |
| ES2393135T3 (es) | 2006-12-29 | 2012-12-18 | Abbott Laboratories | Ensayo mejorado para fármacos inmunosupresores |
| ES2405364T3 (es) | 2006-12-29 | 2013-05-30 | Abbott Laboratories | Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera |
| US7914999B2 (en) | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
| WO2008082984A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
| CA2937492C (en) * | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
| WO2011024168A2 (en) | 2009-08-26 | 2011-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
| US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
| JP2015512371A (ja) | 2012-03-23 | 2015-04-27 | ザ・ユニバーシティ・オブ・クイーンズランド | 免疫調節性作用物質およびその使用 |
| WO2014184734A1 (en) | 2013-05-14 | 2014-11-20 | Novartis Ag | Markers associated with mtor inhibition |
| WO2015044854A1 (en) | 2013-09-24 | 2015-04-02 | Novartis Ag | Markers associated with mtor inhibition |
| CN103933546A (zh) * | 2014-03-27 | 2014-07-23 | 北京科技大学 | 雷帕霉素与环孢素a纳米口服微乳液制备方法 |
| JP7459458B2 (ja) * | 2018-06-28 | 2024-04-02 | ライオン株式会社 | 内服組成物及びその製造方法 |
| WO2023139907A1 (ja) * | 2022-01-24 | 2023-07-27 | 株式会社Moresco | 防腐効果を付与したナノエマルジョン |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1274354A (fr) | 1956-03-10 | 1961-10-27 | Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol | |
| US3244592A (en) | 1962-06-09 | 1966-04-05 | Arai Tadashi | Ascomycin and process for its production |
| GB1380741A (en) * | 1971-02-05 | 1975-01-15 | Squibb & Sons Inc | Antibiotic compositions and their preparation |
| GB1322306A (en) * | 1971-04-15 | 1973-07-04 | Meiji Seika Co | Stabilized antibiotic preparation and manufacturing process therefor |
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| JPS59104326A (ja) * | 1982-12-04 | 1984-06-16 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
| JPS60163823A (ja) * | 1984-02-03 | 1985-08-26 | Taisho Pharmaceut Co Ltd | 経口投与製剤 |
| GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
| ATE126803T1 (de) | 1989-11-09 | 1995-09-15 | Sandoz Ag | Heteroatome enthaltende tricyclische verbindungen. |
| MY110418A (en) | 1990-07-02 | 1998-05-30 | Novartis Ag | Heteroatoms-containing tricyclic compounds. |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| HUT66531A (en) | 1992-05-07 | 1994-12-28 | Sandoz Ag | Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them |
| DE9208647U1 (de) | 1992-06-27 | 1992-09-24 | Rademacher, Antje, 4980 Bünde | Stäbchen zur Reinigung von Ohrring-Löchern |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5234140A (en) | 1992-07-28 | 1993-08-10 | S. C. Johnson & Son, Inc. | Re-useable aerosol container |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| CZ278863B6 (en) * | 1992-09-07 | 1994-07-13 | Galena | Medicinal preparations with n-methylated cyclic undecapeptides |
| DK0589843T3 (da) * | 1992-09-25 | 2002-04-02 | Novartis Ag | Cyclosporinholdige farmaceutiske præparater |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| FR2697040B1 (fr) | 1992-10-21 | 1994-12-30 | Ind Entreprise | Elément de protection contre le bruit et son utilisation. |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| DK1033128T4 (da) * | 1993-09-28 | 2012-03-19 | Scherer Gmbh R P | Blød gelatinekapselfremstilling |
| AU688782B2 (en) * | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
| EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
-
1995
- 1995-10-24 MY MYPI95003195A patent/MY129435A/en unknown
- 1995-10-24 IL IL11574295A patent/IL115742A/xx not_active IP Right Cessation
- 1995-10-24 PE PE1995282786A patent/PE52896A1/es not_active Application Discontinuation
- 1995-10-24 IL IL12954795A patent/IL129547A/xx not_active IP Right Cessation
- 1995-10-25 CN CNA2005100712990A patent/CN1679938A/zh active Pending
- 1995-10-25 CA CA002200967A patent/CA2200967C/en not_active Expired - Fee Related
- 1995-10-25 ES ES95937005T patent/ES2316150T3/es not_active Expired - Lifetime
- 1995-10-25 KR KR1019970702753A patent/KR100541198B1/ko not_active Expired - Fee Related
- 1995-10-25 EP EP95937005A patent/EP0787011B1/en not_active Expired - Lifetime
- 1995-10-25 BR BR9509496A patent/BR9509496A/pt not_active Application Discontinuation
- 1995-10-25 HU HU9701512A patent/HU225535B1/hu not_active IP Right Cessation
- 1995-10-25 DE DE19581805T patent/DE19581805T1/de not_active Withdrawn
- 1995-10-25 JP JP8514302A patent/JPH10509699A/ja active Pending
- 1995-10-25 AU AU39248/95A patent/AU714360B2/en not_active Ceased
- 1995-10-25 CZ CZ19971231A patent/CZ289838B6/cs not_active IP Right Cessation
- 1995-10-25 SK SK521-97A patent/SK285809B6/sk not_active IP Right Cessation
- 1995-10-25 WO PCT/EP1995/004187 patent/WO1996013273A1/en not_active Ceased
- 1995-10-25 AT AT95937005T patent/ATE411800T1/de not_active IP Right Cessation
- 1995-10-25 EP EP08166971A patent/EP2039358A1/en not_active Withdrawn
- 1995-10-25 CN CN95195882A patent/CN1124157C/zh not_active Expired - Fee Related
- 1995-10-25 KR KR10-2004-7010131A patent/KR100518135B1/ko not_active Expired - Fee Related
- 1995-10-25 PT PT95937005T patent/PT787011E/pt unknown
- 1995-10-25 DE DE69535869T patent/DE69535869D1/de not_active Expired - Fee Related
- 1995-10-25 SK SK5048-2005A patent/SK286178B6/sk not_active IP Right Cessation
- 1995-10-25 NZ NZ295655A patent/NZ295655A/xx not_active IP Right Cessation
- 1995-10-26 TR TR97/00299A patent/TR199500299A2/xx unknown
- 1995-10-26 TR TR95/01321A patent/TR199501321A2/xx unknown
- 1995-11-22 TW TW084112417A patent/TW308544B/zh active
-
1997
- 1997-03-10 FI FI970995A patent/FI119497B/fi active IP Right Grant
- 1997-03-25 PL PL95319691A patent/PL184368B1/pl not_active IP Right Cessation
- 1997-04-24 NO NO19971898A patent/NO323078B1/no not_active IP Right Cessation
-
1999
- 1999-04-22 IL IL12954799A patent/IL129547A0/xx unknown
-
2000
- 2000-12-01 CY CY0000066A patent/CY2210B1/xx unknown
-
2002
- 2002-04-20 CN CN02118150A patent/CN1404833A/zh active Pending
-
2003
- 2003-04-28 NO NO20031901A patent/NO323063B1/no not_active IP Right Cessation
-
2004
- 2004-08-25 JP JP2004245057A patent/JP2004359696A/ja active Pending
-
2005
- 2005-05-20 JP JP2005148267A patent/JP2005247870A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUT76858A (en) | Microemulsion pre-concentrate | |
| EP1354582A3 (en) | Emulsion preconcentrates containing cyclosporin or a macrolide | |
| CA2320182A1 (en) | Compositions containing organic compounds | |
| WO2000074661A3 (en) | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use | |
| CA2338358A1 (en) | Compounds and compositions for delivering active agents | |
| CY2285B1 (en) | Liquid compositions containing cyclosporin and process for their preparation | |
| CA2133175A1 (en) | Rapamycin formulations for oral administration | |
| IS4675A (is) | Örþeytur til að nota sem burðarefni við inngjöf virkra efna | |
| EP0993831A3 (en) | Compounds and compositions for delivering active agents | |
| AU5068999A (en) | Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier | |
| IL122905A0 (en) | Pharmaceutical compositions form of a solid dispersion comprising a rapamycin or 33-epi-chloro-33-desoxy-ascomycin | |
| ATE226451T1 (de) | Verfahren zum lösen von pharmazeutischen wirkstoffen in wasser und in wässrige träger | |
| NL300055I2 (nl) | Rapamycinepreparaten voor orale toediening. | |
| CA2141964A1 (en) | Pharmaceutical agents containing diphosphonic acids and salts thereof | |
| CA2273272A1 (en) | Immediate release drug delivery forms | |
| FR2701478B1 (fr) | Dérivés de vitamine E contenant de l'azote quaternaire et procédés pour leur préparation. | |
| ECSP951565A (es) | Composiciones farmaceuticas | |
| CY1109190T1 (el) | Φαρμακευτικα σκευασματα για παρεντερικη χορηγηση τα οποια περιεχουν εποθιλονη |